AllPennyStocks.com Summit’s Global Lung Cancer Trials Gain Credibility After Akeso’s Phase 3 Data, Says Guggenheim
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Summit’s Global Lung Cancer Trials Gain Credibility After Akeso’s Phase 3 Data, Says Guggenheim

Akeso reported positive late-stage data for Ivonescimab, a drug that Summit Therapeutics holds the rights to develop and sell outside China.

Other Penny Stock Movers

$500 Million AI Merger Sends This Microcap Soaring
Colombian Oil Producer Jumps as Q2 Revenue More Than Doubles
Medtech Developer Surges on Triple-Digit EBITDA Growth
Most Popular
{{ index + 1 }}
AllPennyStocks.com Favorites


Back to Top